- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 186215, 8 pages
Gene Therapy and Cell-Based Therapies for Therapeutic Angiogenesis in Peripheral Artery Disease
1Division of Vascular Medicine and Epigenetics, Department of Child Development, United Graduate School of Child Development, Osaka University, Kanazawa University, and Hamamatsu University School of Medicine, 2-1 Yamadaoka, Suita 565-0817, Osaka, Japan
2Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan
Received 16 August 2013; Accepted 9 September 2013
Academic Editor: Ken Suzuki
Copyright © 2013 Munehisa Shimamura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003.
- N. Ferrara and K. Alitalo, “Clinical applications of angiogenic growth factors and their inhibitors,” Nature Medicine, vol. 5, no. 12, pp. 1359–1364, 1999.
- J. M. Isner, A. Pieczek, R. Schainfeld et al., “Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb,” The Lancet, vol. 348, no. 9024, pp. 370–374, 1996.
- I. Baumgartner, A. Pieczek, O. Manor et al., “Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia,” Circulation, vol. 97, no. 12, pp. 1114–1123, 1998.
- J. M. Isner, I. Baumgartner, G. Rauh et al., “Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results,” Journal of Vascular Surgery, vol. 28, no. 6, pp. 964–975, 1998.
- K. Mäkinen, H. Mannine, M. Hedman et al., “Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study,” Molecular Therapy, vol. 6, no. 1, pp. 127–133, 2002.
- S. Rajagopalan, M. Shah, A. Luciano, R. Crystal, and E. G. Nabel, “Adenovirus-mediated gene transfer of VEGF121 improves lower-extremity endothelial function and flow reserve,” Circulation, vol. 104, no. 7, pp. 753–755, 2001.
- Y. H. Kusumanto, V. van Weel, N. H. Mulder et al., “Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial,” Human Gene Therapy, vol. 17, no. 6, pp. 683–691, 2006.
- S. Rajagopalan, E. R. Mohler III, R. J. Lederman et al., “Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication,” Circulation, vol. 108, no. 16, pp. 1933–1938, 2003.
- K. Muona, K. Mäkinen, M. Hedman, H. Manninen, and S. Ylä-Herttuala, “10-Year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb,” Gene Therapy, vol. 19, no. 4, pp. 392–395, 2012.
- A. J. Comerota, R. C. Throm, K. A. Miller et al., “Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial,” Journal of Vascular Surgery, vol. 35, no. 5, pp. 930–936, 2002.
- S. Nikol, I. Baumgartner, E. van Belle et al., “Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia,” Molecular Therapy, vol. 16, no. 5, pp. 972–978, 2008.
- H. Shigematsu, K. Yasuda, T. Iwai et al., “Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia,” Gene Therapy, vol. 17, no. 9, pp. 1152–1161, 2010.
- J. Belch, W. R. Hiatt, I. Baumgartner et al., “Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia,” The Lancet, vol. 377, no. 9781, pp. 1929–1937, 2011.
- R. Morishita, H. Makino, M. Aoki et al., “Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 713–720, 2011.
- T. Nakamura and S. Mizuno, “The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine,” Proceedings of the Japan Academy B, vol. 86, no. 6, pp. 588–610, 2010.
- T. Kaga, H. Kawano, M. Sakaguchi, T. Nakazawa, Y. Taniyama, and R. Morishita, “Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor,” Vascular Pharmacology, vol. 57, no. 1, pp. 3–9, 2012.
- R. Morishita, S. Nakamura, S.-I. Hayashi et al., “Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy,” Hypertension, vol. 33, no. 6, pp. 1379–1384, 1999.
- S.-I. Hayashi, R. Morishita, S. Nakamura et al., “Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells,” Circulation, vol. 100, no. 19, pp. II301–II308, 1999.
- Y. Taniyama, R. Morishita, K. Hiraoka et al., “Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes,” Circulation, vol. 104, no. 19, pp. 2344–2350, 2001.
- Y. Taniyama, R. Morishita, M. Aoki et al., “Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease,” Gene Therapy, vol. 8, no. 3, pp. 181–189, 2001.
- K. Hiraoka, H. Koike, S. Yamamoto et al., “Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA,” Circulation, vol. 108, no. 21, pp. 2689–2696, 2003.
- H. Koike, R. Morishita, S. Iguchi et al., “Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene,” The FASEB Journal, vol. 17, no. 6, pp. 779–781, 2003.
- H. Makino, M. Aoki, N. Hashiya, et al., “Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, pp. 2503–2509, 2012.
- R. J. Powell, M. Simons, F. O. Mendelsohn et al., “Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia,” Circulation, vol. 118, no. 1, pp. 58–65, 2008.
- T. D. Henry, A. T. Hirsch, J. Goldman et al., “Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study,” Gene Therapy, vol. 18, no. 8, pp. 788–794, 2011.
- M. Saeed, A. Martin, P. Ursell et al., “MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium,” Radiology, vol. 249, no. 1, pp. 107–118, 2008.
- E. Tateishi-Yuyama, H. Matsubara, T. Murohara et al., “Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial,” The Lancet, vol. 360, no. 9331, pp. 427–435, 2002.
- K. Esato, K. Hamano, T.-S. Li et al., “Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease,” Cell Transplantation, vol. 11, no. 8, pp. 747–752, 2002.
- P. Huang, S. Li, M. Han, Z. Xiao, R. Yang, and Z. C. Han, “Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes,” Diabetes Care, vol. 28, no. 9, pp. 2155–2160, 2005.
- K. Miyamoto, K. Nishigami, N. Nagaya, et al., “Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans,” Circulation, vol. 114, pp. 2679–2684, 2006.
- S. Durdu, A. R. Akar, M. Arat, T. Sancak, N. T. Eren, and U. Ozyurda, “Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans,” Journal of Vascular Surgery, vol. 44, no. 4, pp. 732–739, 2006.
- M. Arai, Y. Misao, H. Nagai et al., “Granulocyte colony-stimulating factor—a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease,” Circulation Journal, vol. 70, no. 9, pp. 1093–1098, 2006.
- P. P. Huang, X. F. Yang, S. Z. Li, J. C. Wen, Y. Zhang, and Z. C. Han, “Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans,” Thrombosis and Haemostasis, vol. 98, no. 6, pp. 1335–1342, 2007.
- A. Kawamoto, M. Katayama, N. Handa et al., “Intramuscular transplantation of G-CSF-mobilized CD34+ cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial,” Stem Cells, vol. 27, no. 11, pp. 2857–2864, 2009.
- V. Procházka, J. Gumulec, F. Jalůvka et al., “Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer,” Cell Transplantation, vol. 19, no. 11, pp. 1413–1424, 2010.
- M. P. Murphy, J. H. Lawson, B. M. Rapp et al., “Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia,” Journal of Vascular Surgery, vol. 53, no. 6, pp. 1565.e1–1574.e1, 2011.
- D. Lu, B. Chen, Z. Liang et al., “Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial,” Diabetes Research and Clinical Practice, vol. 92, no. 1, pp. 26–36, 2011.
- D. H. Walter, H. Krankenberg, J. O. Balzer et al., “Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia a randomized-start, placebo-controlled pilot trial (PROVASA),” Circulation, vol. 4, no. 1, pp. 26–37, 2011.
- R. J. Powell, W. A. Marston, S. A. Berceli et al., “Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial,” Molecular Therapy, vol. 20, no. 6, pp. 1280–1286, 2012.
- D. W. Losordo, M. R. Kibbe, F. Mendelsohn, et al., “A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia,” Circulation, vol. 5, pp. 821–830, 2012.
- G. O. Ouma, R. A. Jonas, M. H. Usman, and E. R. Mohler III, “Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease,” Vascular Medicine, vol. 17, no. 3, pp. 174–192, 2012.
- G. P. Fadini, C. Agostini, and A. Avogaro, “Autologous stem cell therapy for peripheral arterial disease. Meta-analysis and systematic review of the literature,” Atherosclerosis, vol. 209, no. 1, pp. 10–17, 2010.
- E. Benoit, T. F. O'Donnell, and A. N. Patel, “Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review,” Cell Transplantation, vol. 22, no. 3, pp. 545–562, 2013.
- M. Teraa, R. W. Sprengers, Y. van der Graaf, C. E. Peters, F. L. Moll, and M. C. Verhaar, “Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials,” Annals of Surgery, 2013.
- T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of putative progenitor endothelial cells for angiogenesis,” Science, vol. 275, no. 5302, pp. 964–967, 1997.
- M. Matthias, N. David, and N. Josef, “From bench to bedside: what physicians need to know about endothelial progenitor cells,” American Journal of Medicine, vol. 124, no. 6, pp. 489–497, 2011.
- Z. Raval and D. W. Losordo, “Cell therapy of peripheral arterial disease from experimental findings to clinical trials,” Circulation Research, vol. 112, pp. 1288–1302, 2013.
- M. Kinoshita, Y. Fujita, M. Katayama, et al., “Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia,” Atherosclerosis, vol. 224, pp. 440–445, 2012.
- R. K. Burt, A. Testori, Y. Oyama et al., “Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia,” Bone Marrow Transplantation, vol. 45, no. 1, pp. 111–116, 2010.
- O. M. Tepper, R. D. Galiano, J. M. Capla et al., “Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures,” Circulation, vol. 106, no. 22, pp. 2781–2786, 2002.
- Y. P. R. Jarajapu and M. B. Grant, “The promise of cell-based therapies for diabetic complications: challenges and solutions,” Circulation Research, vol. 106, no. 8, pp. 854–869, 2010.
- Y. P. R. Jarajapu, S. Caballero, A. Verma et al., “Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells,” Investigative Ophthalmology & Visual Science, vol. 52, no. 8, pp. 5093–5104, 2011.
- Y. Taniyama, K. Tachibana, K. Hiraoka et al., “Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle,” Gene Therapy, vol. 9, no. 6, pp. 372–380, 2002.